Evaluation of Varicella Immunity during Pregnancy in Apulia Region, Southern Italy.
Apulia region
Italy
pregnancy
varicella-zoster virus
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
10 May 2020
10 May 2020
Historique:
received:
17
04
2020
revised:
07
05
2020
accepted:
08
05
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
14
5
2020
Statut:
epublish
Résumé
Varicella is a highly contagious, infectious disease caused by the varicella-zoster virus. Those at higher risk of severe complications are immunocompromised individuals, adults, non-immune pregnant women, and newborns. According to the gestational time, when varicella-zoster virus infection is acquired during pregnancy, serious complications can potentially occur for both the woman and the fetus. The present study was conducted to assess the profile of varicella susceptibility in pregnant women in Apulia, a large region in Southern Italy, from 2016 to 2019. The data showed that pregnant women between the age of 15-24 and 40-49 years, the youngest and the oldest, respectively, are the most protected against varicella-zoster virus infection, exceeding the prevalence rate of 90%. Conversely, pregnant women between the age of 25 and 34 years seem to be the most vulnerable and the most at risk for acquiring varicella-zoster virus infection during pregnancy. Analysis of the immunity status against varicella should be introduced as a screening test before pregnancy, together with a strategic vaccination campaign targeting non-immune women of childbearing age, in order to reduce the risk of congenital and perinatal varicella.
Identifiants
pubmed: 32397576
pii: vaccines8020214
doi: 10.3390/vaccines8020214
pmc: PMC7348821
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40
pubmed: 17585291
Vaccine. 2007 Aug 10;25(32):6086-8
pubmed: 17629374
J Egypt Public Health Assoc. 2019;94(1):2
pubmed: 30686830
PLoS One. 2019 Aug 13;14(8):e0221084
pubmed: 31408478
Hum Vaccin Immunother. 2015;11(1):214-9
pubmed: 25483538
Epidemiol Infect. 2001 Jun;126(3):433-40
pubmed: 11467800
J Infect Dis. 2008 Mar 1;197 Suppl 2:S178-84
pubmed: 18419394
BMJ Paediatr Open. 2019 May 30;3(1):e000433
pubmed: 31263790
Prenat Diagn. 2012 Jun;32(6):511-8
pubmed: 22514124
Epidemiol Infect. 2007 Nov;135(8):1344-53
pubmed: 17445317
Hum Vaccin Immunother. 2019;15(12):2851-2853
pubmed: 31184988
Vaccine. 2018 Mar 7;36(11):1435-1443
pubmed: 29428176
J Clin Virol. 2012 Jan;53(1):72-6
pubmed: 22074933
Hum Vaccin Immunother. 2020 Apr 2;16(4):895-898
pubmed: 31674859
BMC Infect Dis. 2019 Apr 29;19(1):356
pubmed: 31035950
Hum Vaccin Immunother. 2017 Feb;13(2):385-390
pubmed: 28027004
N Engl J Med. 1994 Mar 31;330(13):901-5
pubmed: 8114861
Med Microbiol Immunol. 2007 Jun;196(2):95-102
pubmed: 17180380
Vaccine. 2014 Nov 12;32(48):6544-7
pubmed: 25236583
Wkly Epidemiol Rec. 2014 Jun 20;89(25):265-87
pubmed: 24983077
J Matern Fetal Neonatal Med. 2011 Feb;24(2):341-7
pubmed: 20670093